Pacira Pharmaceuticals (NASDAQ:PCRX) had its target price decreased by equities research analysts at Wedbush from $72.00 to $80.00 in a report released on Monday. The firm currently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 139.16% from the company’s current price. Wedbush also issued estimates for Pacira Pharmaceuticals’ Q1 2018 earnings at ($0.14) EPS, Q2 2018 earnings at ($0.12) EPS, Q3 2018 earnings at ($0.22) EPS, Q4 2018 earnings at ($0.13) EPS, FY2018 earnings at ($0.60) EPS, FY2019 earnings at ($1.09) EPS, FY2020 earnings at ($0.25) EPS, FY2021 earnings at $1.36 EPS and FY2022 earnings at $1.89 EPS.
PCRX has been the topic of several other reports. JPMorgan Chase restated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, January 4th. Canaccord Genuity upped their price objective on shares of Pacira Pharmaceuticals from $32.00 to $34.00 and gave the stock a “hold” rating in a report on Monday. BidaskClub lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. ValuEngine lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 17th. Finally, Zacks Investment Research lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $44.35.
Shares of PCRX stock traded down $1.10 during trading hours on Monday, hitting $33.45. The company had a trading volume of 1,628,686 shares, compared to its average volume of 1,212,933. The company has a debt-to-equity ratio of 0.99, a quick ratio of 6.22 and a current ratio of 6.96. Pacira Pharmaceuticals has a fifty-two week low of $26.95 and a fifty-two week high of $52.47.
A number of institutional investors and hedge funds have recently made changes to their positions in PCRX. First Republic Investment Management Inc. purchased a new stake in Pacira Pharmaceuticals during the 4th quarter worth approximately $201,000. Bouchey Financial Group Ltd purchased a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at approximately $205,000. Twin Focus Capital Partners LLC purchased a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at approximately $206,000. Redmile Group LLC purchased a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at approximately $237,000. Finally, Fisher Asset Management LLC purchased a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at approximately $241,000.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.